Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors

Clinical Cancer Research

Volumn 9, Issue 11, 2003, Pages 4101-4107

  Gelderblom, Hans ^a,d   Salazar, Ramon ^b   Verweij, Jaap ^a   Pentheroudakis, George ^b   De Jonge, Maja J A ^a   Devlin, Martin ^b   Van Hooije, Christel ^a   Seguy, Francis ^c   Obach, Rosendo ^c   Pruñonosa, Joan ^c   Principe, Paola ^c   Twelves, Chris ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c IPSEN   (France)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BN809015; CAMPTOTHECIN DERIVATIVE; DIFLOMOTECAN; LACTONE;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; VERTIGO;

ADMINISTRATION, ORAL; ADULT; AGED; ALOPECIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; CAMPTOTHECIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS;

EID: 0141455147     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Lavergne, O., Lesueur-Ginot, L., Pla Rodas, F., Kasprzyk, P. G., Pommier, J., Demarquay, D., Prevost, G., Ulibarri, G., Rolland, A., Schiano-Liberatore, A. M., Harnett, J., Pons, D., Camara, J., and Bigg, D. C. H. Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. J. Med. Chem., 41: 5410-5419, 1998.
2. Bailly, C., Lansiaux, A., Dassonneville, L., Demarquay, D., Coulomb, H., Huchet, M., Lavergne, O., and Bigg, D. C. H. Homocamptothecin, an E-ring modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks. Biochemistry, 38: 15556-15563, 1999.
3. Demarquay, D., Huchet, M., Coulomb, H., Lesueur-Ginot, L., Lavergne, O., Kasprzyk, P. G., Bailly, C., Camera, C., and Bigg, D. C. H. The homocamptothecin BN80915 is a highly potent orally active topoisomerase I poison. Anticancer Drugs, 12: 9-19, 2001.
4. Principe, P., Marsais, J., Kasprzyk, P. G., Carlson, M., Lauer, J., Meshaw, K., Alford, T. L., Hill, B., Chen, S. F., Hollister, B. A., and Dexter, D. L. Anti-tumour profile of diflomotecan, a novel E-ring modified topoisomerase I inhibitor, Nov. 16-19, 1999. Washington, DC: AACR-NCI-EORTC International Conference, 1999, p. 134.
5. Lesueur-Ginot, L., Demarquay, D., Kiss, R., Dassonneville, L., Bailly, C., Camara, J., Lavergne, O., and Bigg, D. C. H. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Cancer Res., 59: 2939-2943, 1999.
6. Larsen, A. K., Gilbert, C., Chyzak, G., Plisov, S. Y., Naguibneva, I., Lavergne, O., Lesueur-Ginot, L., and Bigg, D. C. H. Unusual potency of BN80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells. Cancer Res., 61: 2961-2967, 2001.
7. Philippart, P., Harper, L., Chaboteaux, C., Decaestecker, C., Bronckart, Y., Gordover, L., Lesueur-Ginot, L., Malonne, H., Lavergne, O., Bigg, D. C. H., Mendes da Costa, P., and Kiss, R. Homocamptothecin, an E-ring-modified camptothecin exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions. Clin. Cancer Res., 6: 1557-1562, 2000.
8. Liu, G., Franssen, E., Fitch, M. I., and Warner, E. Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol., 15: 110-115, 1997.
9. Menargues, A., Celma, C., Cordero, J. A., Basart, D., Obach, R., Peraire, C., and Principe, P. Pharmacokinetics and oral bioavailability of diflomotecan, a novel topoisomerase I inhibitor, after single dose administration in rats, Nov. 16-19, 1999. Washington, DC: AACR-NCI-EORTC International Conference, 1999, p. 112.
10. Pruñonosa, J., Lopez, S., Basart, D., Celma, C., Vilageliu, J., Obach, R., Peraire, C., and Principe, P. Dog pharmacokinetics and oral bioavailability of diflomotecan, a novel topoisomerase I inhibitor, Nov. 16-19, 1999. Washington, DC: AACR-NCI-EORTC International Conference, 1999, p. 110.
11. 14C-diflomotecan, a novel E-ring modified topoisomerase I inhibitor, after single dose administration in rats, Nov. 16-19, 1999. Washington, DC: AACR-NCI-EORTC International Conference, 1999, p. 110.
12. Loos, W. J., Gelderblom, H., Sparreboom, A., Verweij, J., and de Jonge, M. J. A. Inter- and intra-patient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. Clin. Cancer Res., 6: 2685-2689, 2000.
13. Creemers, G. J., Lund, B., and Verweij, J. Topoisomerase I inhibitors; topotecan and irinotecan. Cancer Treat. Rev., 20: 73-96, 1994.
14. Gerrits, C. J. H., Burris, H., Schellens, J. H. M., Planting, A. S., van der Burg, M. E., Rodriguez, G. I., van Beurden, V., Loos, W. J., Hudson, I., Fields, S., Verweij, J., and von Hoff, D. D. Five days of oral topotecan (hycamtin), a Phase I and pharmacological study in adult patients with solid tumours. Eur. J. Cancer, 34: 1030-1035, 1998.
15. De Jonge, M. J. A., Punt, C. J. A., Gelderblom, H., Loos, W. J., van Beurden, V., Planting, A. S., van der Burg, M. E. L., van Maanen, L. W. G. M., Dallaire, B. K., Verweij, J., Wagener, D. J. T., and Sparreboom, A. Phase I and pharmacologic study of oral [PEG-1000] 9-aminocamptothecin in adult patients with solid tumors. J. Clin. Oncol., 17: 2219-2226, 1999.
16. Verschraegen, C., Natelson, E., Giovanella, B. C., Kavanagh, J. J., Kudelka, A. P., Freedman, R. S., Edwards, C. L., Ende, K., and Stehlin, J. C. A Phase I clinical and pharmacological study of oral 9-NC, a novel water soluble topoisomerase I inhibitor. Anticancer Drugs, 9: 36-44, 1998.
17. Verschraegen, C., Gupta, E., Loyer, E., Kavanagh, J. J., Kudelka, A. P., Freedman, R. S., Edwards, C. L., Harris, N., Steger, M., Steltz, V., Giovanella, B. C., and Stehlin, J. C. A Phase II study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anticancer Drugs, 10: 375-384, 1999.
18. Drengler, R. L., Kuhn, J. G., Schaaf, L. J., Rodriguez, G. I., Villalona-Calero, M. A., Hammond, L. A., Stephenson, J. A., Hodges, S., Kraynak, M. A., Staton, B. A., Elfring, G. L., Locker, P. K., Miller, L. L., von Hoff, D. D., and Rothenberg, M. L. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J. Clin. Oncol., 17: 685-696, 1997.
19. von Pawel, J., Gatzemeier, U., Pujal, J-L., Moreau, L., Bildat, S., Ranson, M., Richardson, G., Steppert, C., Riviere, A., Camlett, I., Lane, S., and Ross, G. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J. Clin. Oncol., 19: 1743-1749, 2001.
20. Gelderblom, H., de Jonge, M. J., Sparreboom, A., and Verweij, J. Oral topoisomerase I inhibitors in adult patients: present and future. Investig. New Drugs, 17: 401-415, 1999.